English
Polski
Español
українська
Cytogenetic tests in MPN
Do you perform cytogenetic tests in every patient with a myeloproliferative neoplasm (MPN)?
2020-11-10
Do you perform cytogenetic tests in every patient with a myeloproliferative neoplasm (MPN)?
Do you treat low-risk asymptomatic patients with primary myelofibrosis (PMF)?
How do you reduce the risk of infection in patients treated with ruxolitinib?
Are there any patients with essential thrombocythemia (ET) or polycythemia vera (PV) who do not need antiplatelet treatment?
How to manage patients with secondary polycythemia? Should we perform phlebotomies or administer antiplatelet treatment?
Which cytoreductive drug is your first-line option for the treatment of myeloproliferative neoplasms (MNPs)?
What tests are useful in establishing the cause of secondary polycythemia?
What antithrombotic treatment should be used in a patient with thrombosis and myeloproliferative neoplasms (MPNs)? Should antiplatelet treatment be continued?
What is your approach in a patient with a low burden of JAK2 mutation without other diagnostic criteria for myeloproliferative neoplasms (MPNs)? Does this approach change if the patient has a history of thrombosis?
